DCDB 2.0: a major update of the drug combination database
暂无分享,去创建一个
Xin Chen | Yanbin Liu | Qiang Wei | Yongquan Li | Guisheng Yu | Wanxia Gai | Yongquan Li | Xin Chen | Guisheng Yu | Yanbin Liu | Qiang Wei | Wanxia Gai
[1] Young Suk Park,et al. Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study , 2009, Cancer Chemotherapy and Pharmacology.
[2] Hongkang Mei,et al. Systematic Prediction of Pharmacodynamic Drug-Drug Interactions through Protein-Protein-Interaction Network , 2013, PLoS Comput. Biol..
[3] References , 1971 .
[4] Guan-Hua Lai,et al. Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. , 2003, Molecular cancer therapeutics.
[5] H. Chandler. Database , 1985 .
[6] Razelle Kurzrock,et al. Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non–Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations , 2013, Molecular Cancer Therapeutics.
[7] K. Coleman,et al. In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin. , 1980, The Journal of antimicrobial chemotherapy.
[8] Tianhan Xue,et al. Studying Traditional Chinese Medicine , 2003, Science.
[9] Xiaohua Ma,et al. Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.
[10] K. Fizazi,et al. The role of Src in prostate cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] Yang Song,et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..
[12] Olivier Bodenreider,et al. The Unified Medical Language System (UMLS): integrating biomedical terminology , 2004, Nucleic Acids Res..
[13] Kyoung Mii Park,et al. CDA: Combinatorial Drug Discovery Using Transcriptional Response Modules , 2012, PloS one.
[14] Joel Dudley,et al. Network-Based Elucidation of Human Disease Similarities Reveals Common Functional Modules Enriched for Pluripotent Drug Targets , 2010, PLoS Comput. Biol..
[15] J Henkel,et al. Attacking AIDS with a 'cocktail' therapy? , 1999, FDA consumer.
[16] Henning Hermjakob,et al. The Reactome pathway Knowledgebase , 2015, Nucleic acids research.
[17] Jiehua Zhu,et al. National Natural Science Foundation of China (NSFC) , 2013 .
[18] T. Chou. Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.
[19] David S. Wishart,et al. DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..
[20] David Pérol,et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. , 2011, The Lancet. Oncology.
[21] S. Hursting,et al. Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue , 2012, Annals of the New York Academy of Sciences.
[22] Enrique Casado,et al. Chemotherapy for colorectal cancer in the elderly: Whom to treat and what to use. , 2009, Cancer treatment reviews.
[23] Michele Magrane,et al. UniProt Knowledgebase: a hub of integrated protein data , 2011, Database J. Biol. Databases Curation.
[24] Doheon Lee,et al. Systematic Approach for Analyzing Drug Combination by Using Target-Enzyme Distance , 2013 .
[25] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[26] Susumu Goto,et al. Data, information, knowledge and principle: back to metabolism in KEGG , 2013, Nucleic Acids Res..
[27] Chris Sander,et al. Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets , 2013, Science Signaling.
[28] Ravi Iyengar,et al. Systems Pharmacology of Adverse Event Mitigation by Drug Combinations , 2013, Science Translational Medicine.
[29] Joaquim Bellmunt,et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. , 2013, The Lancet. Oncology.
[30] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[31] Matthew Sperrin,et al. Investigation of the robustness of two models for assessing synergy in pre-clinical drug combination studies. , 2013, Pharmaceutical statistics.
[32] Rafael C. Jimenez,et al. The MIntAct project—IntAct as a common curation platform for 11 molecular interaction databases , 2013, Nucleic Acids Res..
[33] Alan R. Aronson,et al. An overview of MetaMap: historical perspective and recent advances , 2010, J. Am. Medical Informatics Assoc..
[34] Erika Martinelli,et al. Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines , 2013, Clinical Cancer Research.
[35] Xin Chen,et al. Human interactome resource and gene set linkage analysis for the functional interpretation of biologically meaningful gene sets , 2013, Bioinform..
[36] Eunyoung Kang,et al. Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR) , 2014, BMC Cancer.
[37] Liang Liu,et al. Network-based drug discovery by integrating systems biology and computational technologies , 2012, Briefings Bioinform..
[38] Lei Huang,et al. DrugComboRanker: drug combination discovery based on target network analysis , 2014, Bioinform..
[39] Yanli Wang,et al. PubChem applications in drug discovery: a bibliometric analysis. , 2014, Drug discovery today.
[40] J. Lehár,et al. Systematic discovery of multicomponent therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[41] Axel Hauschild,et al. Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha‐2b in metastatic melanoma (phase II DeCOG trial) , 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[42] F. Sörgel,et al. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans , 1995, Clinical pharmacology and therapeutics.
[43] Luke A. Gilbert,et al. Defining principles of combination drug mechanisms of action , 2012, Proceedings of the National Academy of Sciences.
[44] Tudor I. Oprea,et al. Drug Repurposing from an Academic Perspective. , 2011, Drug discovery today. Therapeutic strategies.
[45] Bo Zhang,et al. Network target for screening synergistic drug combinations with application to traditional Chinese medicine , 2011, BMC Systems Biology.